Invention Grant
- Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
-
Application No.: US15988763Application Date: 2018-05-24
-
Publication No.: US10253018B2Publication Date: 2019-04-09
- Inventor: Guoqiang Wang , Brett Granger , Ruichao Shen , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Jing He , Bin Wang , Yat Sun Or
- Applicant: ENANTA PHARMACEUTICALS, INC.
- Applicant Address: US MA Watertown
- Assignee: ENANTA PHARMACEUTICALS, INC.
- Current Assignee: ENANTA PHARMACEUTICALS, INC.
- Current Assignee Address: US MA Watertown
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore, Esq.
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D401/04 ; C07D491/107 ; C07D498/08

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Public/Granted literature
- US20180362501A1 Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof Public/Granted day:2018-12-20
Information query